Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prognostic impact of circulating plasma cells in patients with multiple myeloma, implications for plasma cell leukemia definition

  • Granell, Miquel|||0000-0002-0366-3673
  • Calvo, Xavier|||0000-0001-7934-9130
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Abella Monreal, Eugenia|||0000-0001-9605-8458
  • Martínez, Clara Mª
  • Teixidó, Montserrat
  • Gimenez, Mª Teresa
  • Senín, Alicia
  • Sanz, Patricia
  • Campoy, Desirée
  • Vicent, Ana
  • Arenillas, Leonor|||0000-0002-9020-8766
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Sierra, Jorge|||0000-0002-7966-0356
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Fernandez de Larrea Rodriguez, Carlos
The presence of circulating plasma cells in patients with multiple myeloma is considered a marker for highly proliferative disease. In the study herein, the impact of circulating plasma cells assessed by cytology on survival of patients with multiple myeloma was analyzed. Wright-Giemsa stained peripheral blood smears of 482 patients with newly diagnosed myeloma or plasma cell leukemia were reviewed and patients were classified into 4 categories according to the percentage of circulating plasma cells: 0%, 1-4%, 5-20%, and plasma cell leukemia with the following frequencies: 382 (79.2%), 83 (17.2%), 12 (2.5%) and 5 (1.0%), respectively. Median overall survival according to the circulating plasma cells group was 47, 50, 6 and 14 months, respectively. At multivariate analysis, the presence of 5 to 20% circulating plasma cells was associated with a worse overall survival (relative risk 4.9, 95% CI 2.6-9.3) independently of age, creatinine, the Durie-Salmon system stage and the International Staging System (ISS) stage. Patients with ≥5% circulating plasma cells had lower platelet counts (median 86×10 9 /L vs. 214×10 9 /L, P <0.0001) and higher bone marrow plasma cells (median 53% vs. 36%, P =0.004). The presence of ≥5% circulating plasma cells in patients with multiple myeloma has a similar adverse prognostic impact as plasma cell leukemia.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease

  • Isola, Ignacio
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Moreno, David F.
  • Mena, Mari Pau
  • Oliver-Caldés, Aina|||0000-0002-7921-5420
  • Paré Brunet, Laia
  • Rodríguez Lobato, Luis Gerardo|||0000-0001-5694-0921
  • Martín-Antonio, B|||0000-0003-0612-2693
  • Cibeira, María Teresa|||0000-0002-4036-754X
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Prat, Aleix|||0000-0003-2377-540X
  • Lozano, Ester|||0000-0002-6307-9807
  • Fernández de Larrea, Carlos|||0000-0003-4930-9255
Background: We previously reported algorithms based on clinical parameters and plasma cell characteristics to identify patients with smoldering multiple myeloma (SMM) with higher risk of progressing who could benefit from early treatment. In this work, we analyzed differences in the immune bone marrow (BM) microenvironment in SMM to better understand the role of immune surveillance in disease progression and to identify immune biomarkers associated to higher risk of progression. Methods: Gene expression analysis of BM cells from 28 patients with SMM, 22 patients with monoclonal gammopathy of undetermined significance (MGUS) and 22 patients with symptomatic MM was performed by using Nanostring Technology. Results: BM cells in SMM compared to both MGUS and symptomatic MM showed upregulation of genes encoding for key molecules in cytotoxicity. However, some of these cytotoxic molecules positively correlated with inhibitory immune checkpoints, which may impair the effector function of BM cytotoxic cells. Analysis of 28 patients with SMM revealed 4 distinct clusters based on immune composition and activation markers. Patients in cluster 2 showed a significant increase in expression of cytotoxic molecules but also inhibitory immune checkpoints compared to cluster 3, suggesting the presence of cytotoxic cells with an exhausted phenotype. Accordingly, patients in cluster 3 had a significantly longer progression free survival. Finally, individual gene expression analysis showed that higher expression of TNF superfamily members (TNF, TNFAIP3, TNFRSF14) was associated with shorter progression free survival. Conclusions: Our results suggest that exhausted cytotoxic cells are associated to high-risk patients with SMM. Biomarkers overexpressed in patients with this immune gene profile in combination with clinical parameters and PC characterization may be useful to identify SMM patients with higher risk of progression.